The following is a summary of “Novel protein C variant p.C101F results in early intracellular degradation that drives type I ...
The hybrid-ribosome observation is convincing, but additional information on the choice of cycloheximide concentration would be helpful to rule out other interpretations. The experiment on translation ...
The deyolking buffer was supplemented with 1x protease inhibitors (EDTA-free, Roche) and 0.1 μg/mL cycloheximide. To avoid DNA contamination in the higher molecular weight factions, obtained larval ...
FIGURE 3. KDM5C R1115H is stable in cells. Lymphoblastoid cell lines from father (UM1-II-1, KDM5C WT) and proband (UM1-III-3, KDM5C R1115H) were treated with a cycloheximide (CHX) time course from 0 ...
Cycloheximide was purchased from Amresco (97064-722, WA, United States), and proteasome inhibitor MG132 (S2619) and Bortezomib (S1013) were acquired from Selleck Chemicals (Houston, United States).
Background Schaaf-Yang syndrome (SYS) is caused by truncating mutations in MAGEL2, mapping to the Prader-Willi region (15q11-q13), with an observed phenotype partially overlapping that of Prader-Willi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results